New DMPs (disease management programmes) fail to target high blood pressure
This article was originally published in Clinica
A decision by the working group of the co-ordination committee of the German health service to omit high blood pressure treatment from the first four disease management programmes (DMPs) could have a negative impact on medical device companies operating in this field. Social Democratic MP Klaus Kirschner, chairman of the parliamentary health committee, has strongly objected to the omission, claiming that the illness affects 30% of German men and 27% of German women between the ages of 25-69. "If the sickness funds introduced a DMP for high blood pressure, we could avoid some 25,000 heart attacks per year," he said.
You may also be interested in...
Biogen value-based contract with UPMC Health Plan ties payments to patient-reported outcomes for Tecfidera and Avonex. The company may seek something similar for Vumerity.
As interest in immune/inflammatory disease increases and savings achieved dip, payer focus on patient-reported outcomes for contracts reflects shift in focus, Avalere survey suggests.
After an eleventh-hour win last year that saw Congress repeal the medical device excise tax, AdvaMed is going more global. CEO Scott Whitaker sat down with Medtech Insight for a lengthy chat about what the lobby group will focus on in 2020, including reimbursement challenges, the upcoming medical device user-fee negotiations, and negotiations with governments that are key to the industry ecosystem.